Alzheimer’s & Dementia

The approval of lecanemab and donanemab has transformed Alzheimer’s disease into a treatable condition for patients with early symptomatic disease and confirmed amyloid pathology. GCNN 2027 will present long-term CLARITY-AD and TRAILBLAZER-ALZ open-label extension data, real-world ARIA-E and ARIA-H rates stratified by APOE4 status, and operational models for safe infusion-clinic delivery. Sessions will examine the rapid emergence of plasma p-tau217 as a triage biomarker rivaling CSF and amyloid-PET, the next-wave tau-directed therapeutics, and GLP-1 receptor agonists (evoke, evoke+) as a potential disease-modifying class.